Predicting the risk of coronary heart disease. II: The role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 352-362

  Dent, T H S ^a  

^a PHG FOUNDATION   (United Kingdom)

Author keywords

Conventional risk factors; Coronary heart disease; Genetics; Novel biomarkers; Risk prediction

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HOMOCYSTEINE; LIPOPROTEIN A; PHOSPHOLIPASE A2; URIC ACID;

CARDIOVASCULAR RISK; DISEASE MARKER; GENETIC MARKER; GENETIC RISK; HUMAN; ISCHEMIC HEART DISEASE; MULTIFACTORIAL INHERITANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; CYSTATIN C; FIBRINOGEN; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; NATRIURETIC PEPTIDE, BRAIN; RISK; RISK ASSESSMENT; RISK FACTORS; URIC ACID;

EID: 78649725232     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.021     Document Type: Review

References (52)

1. Magnus P., Beaglehole R. The real contribution of the major risk factors to the coronary epidemics. Arch Intern Med 2001, 161:2657-2660.
2. Pepe M.S., Janes H., Longton G., et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890.
3. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statist Med 2008, 27:157-172.
4. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. NEJM 2004, 350:1387-1397.
5. Wilson P.W.F., Nam B.-H., Pencina M., et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005, 165:2473-2478.
6. Shah T., Casas J.P., Cooper J.A., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2008, 1-15. 10.1093/ije/dyn217.
7. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. The Emerging Risk Factors Collaboration.
8. Wilson P.W.F., Pencina M., Jacques P., et al. C-reactive protein and reclassification of cardiovascular risk in the outcomes Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008, 1:92-97.
9. Elliot P., Chambers J.C., Shang W., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37-48.
10. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005, 294:1799-1809. Fibrinogen Studies Collaboration.
11. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002, 325:1202.
12. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022. Homocysteine Studies Collaboration.
13. De Sutter J., De Bacquer D., Cuypers S., et al. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study. Eur Heart J 2005, 26:2644-2649.
14. Kistorp C., Raymond I., Pedersen F., et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005, 293:1609-1616.
15. Di Angelantonio E., Chowdhury R., Sarwar N., et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009, 120:2177-2187.
16. Sacks F.M., Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metabol 2003, 88:4525-4532.
17. Rizzo M., Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 2007, 23:14-20.
18. Rizzo M., Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 2006, 99:1-14.
19. Thompson A., Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006, 259:481-492.
20. Bennett A.M., Di Angelantonio E., Ye Z., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007, 298:1300-1311.
21. Garza C.A., Montori V.M., McConnell J.P. Association between lipoprotein-associated phospholipase a2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159-165.
22. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423. The Emerging Risk Factors Collaboration.
23. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008, 117:176-184.
24. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049-2060.
25. Strasak A., Ruttmann E., Brant L., et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008, 54:273-284.
26. Strasak A.M., Kelleher C.C., Brant L.J. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008, 125:232-239.
27. Bos M.J., Koudstaal P.J., Hofman A., et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37:1503-1507.
28. Chien K.L., Hsu H.C., Sung F.C., et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 2005, 183:147-155.
29. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191:391-396.
30. Fraser A., Harris R., Sattar N., et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27:2729-2735.
31. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201:168-175.
32. Ridker P.M., Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004, 109:1955-1959.
33. Folsom A.R., Chambless L.E., Ballantyre C.M., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med 2006, 166:1368-1373.
34. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. NEJM 2006, 355:2631-2639.
35. Melander O., Newton-Cheh C., Almgren P. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009, 302:49-57.
36. Zethelius B., Berglund L., Sundström J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
37. Agarwal A., Williams G.H., Fisher N.D. Genetics of human hypertension. Trends Endocrinol Metab 2005, 16:127-133.
38. Williams R.R., Hunt S.C., Hopkins P.N. Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am J Hypertens 1993, 6:319S-327S.
39. Lloyd-Jones D.M., Nam B.H., D'Agostino R.B., et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004, 291:2204-2211.
40. Wang Q. Molecular basis of coronary artery disease. Curr Opin Cardiol 2005, 20:182-188.
41. McPherson A. Chromosome 9p21 and coronary artery disease. NEJM 2010, 362:1736-1737.
42. Hippisley-Cox J., Coupland C., Vinogradova Y., et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008, 336:1475-1482.
43. Pharoah P.D., Antoniou A.C., Easton D.F., Ponder B.A. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358:2796-2803.
44. Wacholder S., Hartge P., Prentice R., et al. Performance of common genetic variants in breast-cancer risk models. NEJM 2010, 362:986-993.
45. Drenos F., Whittaker J.C., Humphries S. The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk. Ann Hum Genet 2007, 71:1-9.
46. Janssens A.C.J.W., Moonesinghe R., Yang Q., et al. The impact of genotype frequencies on the clinical validity of genomic profiling for predicting common chronic diseases. Genet Med 2007, 9:528-535.
47. Talmud P.J., Cooper J.A., Palmen J., et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem 2008, 54:467-474.
48. Humphries S.E., Cooper J.A., Talmud P.J., Miller G.J. Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin Chem 2007, 53:8-16.
49. Paynter N.P., Chasman D.I., Buring J.E., et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009, 150:65-72.
50. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and riskof cardiovascular events. N Engl J Med 2008, 358:1240-1249.
51. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme (). http://www.screening.nhs.uk/criteria.
52. Anderson J.L. Advances in the detection of rupture-prone plaque: the role of lipoprotein-associated phospholipase a2 in cardiovascular risk assessment. Am J Cardiol 2008, 101:S23-S33.